Advertisement

BUSINESS WIRE)-- AdeTherapeutics, Inc. received Health Canada approval in November to conduct a double-blind randomized placebo controlled study in 30 patients to test its therapeutic to reduce adhesion (scar tissue) formation following laparoscopic procedure to remove an ectopic pregnancy.

The trial will be conducted at teaching hospitals in Canada with first patient enrolment expected in December 2011.

According to the Royal College of Obstetrics & Gynecology Journal Special Report on Adhesions, post-surgical scarring occurs in 93% of surgeries causing serious complications and costly re-admissions.

United States National Institute for Heatlh (NIH) reported that only 1 in 3 women suffering an ectopic are able to have a baby.

The therapeutic is safe and easy to use for surgeons. The drug delivery system includes a common catheter attached to a Luer-Lock adapter. The drug is drawn up in a syringe and attached to the Luer-Lock adapter. At the end of the procedure, the catheter is thread down the trocar and the drug is evenly distributed to the surgical site.

AdeTherapeutics announced today a strategic partnership and collaboration with Numoda Corporation and Numoda Capital Innovations out of Philadelphia, PA, USA. Numoda will be responsible for helping AdeTherapeutics move its extensive portfolio of assets through clinical development, preparing it for regulatory approval and partnering.

"Numoda's experience, resources and systems in executing dependable clinical trials eliminates many of the execution risks, adds value to our products and provides a robust data package for potential partners," said Sanj Singh, AdeTherapeutics' CEO.

"Our Company prides itself in helping promising scientific advances get to market, faster. AdeTherapeutics' work is a prime example. And we have great confidence in this partnership," said Mary Schaheen, Chairman, Numoda.

"This latest partnership is very encouraging. A member of the national industry association, talented companies such as AdeTherapeutics are nimble in their approach and able to capitalize on the opportunities which abound," added Peter Brenders, President and CEO BIOTECanada.

Advertisement
Advertisement